ArticleBMC nephrology2026
Associations of creatinine muscle index with muscle strength and mass in patients with chronic kidney disease initiating dapagliflozin.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe creatinine muscle index (CMI) may reflect muscle mass or strength; however, simultaneous assessment of both in patients with chronic kidney disease (CKD) remains limited. We examined associations of CMI with handgrip strength (HGS) and bioimpedance analysis-estimated skeletal muscle index (SMI) in these patients.
methodsPatients with CKD had HGS and SMI measured at the initiation of dapagliflozin for CKD. Low muscle strength and mass were defined as HGS < 18 kg and SMI < 5.7 kg/m
resultsWe included 97 patients with CKD (men: 73.2%; mean age: 63.6 years; body mass index [BMI]: 24.5 kg/m
conclusionCMI was independently associated with both HGS and SMI in patients with CKD and performed well in identifying low muscle strength and low muscle mass. These findings suggest that CMI may serve as a simple, accessible surrogate marker of muscle status in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.